Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion Infusions's EBIT per Share for the
three
months ended in Mar. 2026 was BDT0.36.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was BDT3.94.
During the past 12 months, the average EBIT per Share Growth Rate of Orion Infusions was -12.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -3.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 1.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -0.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Orion Infusions's EBIT per Share or its related term are showing as below:
DHA:ORIONINFU'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -6.2 Med: 0.9 Max: 16.8
Current: -3.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Orion Infusions was 16.80% per year. The lowest was -6.20% per year. And the median was 0.90% per year.
DHA:ORIONINFU's 3-Year EBIT Growth Rate is ranked worse than 65.97% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs DHA:ORIONINFU: -3.20
Orion Infusions's EBIT for the
three
months ended in Mar. 2026 was BDT7.4 Mil.
Orion Infusions (DHA:ORIONINFU) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Orion Infusions EBIT per Share Related Terms
Orion Infusions EBIT per Share Historical Data
* Premium members only.
The historical data trend for Orion Infusions's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT3.94
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Infusions (DHA:ORIONINFU) has a EBIT per Share of BDT3.94 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Orion Infusions and its competitors. According to the industry distribution chart, Orion Infusions ranks #535 out of 811 companies in the Drug Manufacturers industry, placing it in the top 66%.
Is Orion Infusions' EBIT per Share too high?
Orion Infusions' current EBIT per Share is BDT3.94. Based on the distribution chart, Orion Infusions ranks #535 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orion Infusions has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #535 out of 811 companies for EBIT per Share. This places Orion Infusions in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current EBIT per Share is BDT3.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT316.17, compared to a current price of BDT291.20 — trading 7.9% below its estimated fair value. The current EBIT per Share is BDT3.94. Orion Infusions' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current EBIT per Share is BDT3.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17.
GuruFocus considers Orion Infusions to be Fairly Valued.
Key valuation signals for DHA:ORIONINFU:
EBIT per Share: BDT3.94
GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score
Get the complete analysis for DHA:ORIONINFU
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
